eXp World Holdings, Inc. (OTCQB: EXPI), in a February 3, 2017, SEC 8-K filing (http://dtn.fm/p2rAC), announced that it has changed accounting firms, hiring BDO USA, LLP (BDO) as its registered independent accountant and dismissing WSRP, LLC (WSRP). The change was made effective at the time of announcement.

EXPI originally engaged WSRP, LLC in September 2015. The board of eXp World Holdings approved the change in accounting firms, effective February 3, 2017, for its year ended December 31, 2016. In the SEC filing, EXPI reported that it had no differences with WSRP regarding accounting principles, disclosures in its financial statements, or auditing scope and procedures.

In a January 27, 2017, SEC Form D filing (http://dtn.fm/5UKcB), the company also reported the status of its exempt offering of $3.5 million in securities. It reported that it has recorded sales of $760,000 from 12 investors, leaving EXPI with $2,740,000 remaining to be sold. Proceeds from this offering are expected to be used to fund the company’s working capital for ongoing operations.

eXp World Holdings subsidiary eXp Realty LLC is a cloud brokerage, agent-owned company. It reported 2,401 real estate brokers and agents on its platform at year-end 2016.

The company’s real estate concept utilizes the internet and a cloud-based office environment in order to eliminate redundant payroll costs and cut margin-eroding expenses normally associated with brick-and-mortar operations, such as rent, utility expenses, and furnishings. Instead, EXPI can spend more heavily on training its realtors and agents using advanced technologies.

A Fundamental Research Report (http://dtn.fm/m7IiJ) on the company issued last year projected EXPI’s volume in 2017 at $72 million.

For more information, visit the company’s website at www.eXpWorldHoldings.com

Let us hear your thoughts: eXp World Holdings, Inc. Message Board

According to statistics published at ChinaDaily.com (http://nnw.fm/x8NcC), online sales in China have boomed, growing 26.2% year-on-year to reach over five trillion yuan ($751.7 billion) in 2016. With this in mind, researchers and specialists worldwide are looking at China to learn how to initiate more online purchases, but it is not just China’s developed e-commerce market that has caught people’s attention.

The mobile generation led everyone to focus on mobile marketing, but companies are realizing that they have to cater their services to users across all devices in order to reach their full audience potential. According to a McKinsey survey (http://nnw.fm/3jfV4), titled ‘How savvy, social shoppers are transforming Chinese e-commerce’, multi-device owners spend 17% more money on e-commerce, shop in 29% more categories, and interact 14% more with companies via social media.

McKinsey continued to explain that half of the digital consumers surveyed said that they use social media to do research into a product or get a recommendation. Additionally, of the WeChat users surveyed, over 30% started their buying journeys on the platform. With this in mind, organizations are adapting their social media platforms from simply informational and conversational tools to powerful channels for initiating online purchases.

From now on, social media strategies will need to be savvy if merchants want to keep afloat. This leads us to Moxian, Inc. (NASDAQ: MOXC), a company that offers social media marketing and promotion platforms to help merchants advertise through social media and accelerate business growth.

Through the Moxian+ User app and the Moxian+ Business app, merchants are able to run targeted advertising campaigns and promotions. The Moxian platform integrates entertainment, social media, and business intelligence, which, when combined with social customer relationship management systems, allow for the generation of data for merchants that can then be used to better connect with consumers.

With social media purchases on the rise, organizations are going to have to adapt their social media strategies to better serve a more demanding market. To meet this growing demand, Moxian, Inc. has created a personalized social media platform that is tailored to both consumers and businesses.

For more information, visit www.Moxian.com

National Waste Management Holdings, Inc. (OTC: NWMH) is making a strong play in the waste industry and taking major steps to turn the page on its growth story. Over the course of three decades, the company has become a notable provider of solid waste management services to Florida’s west coast and New York’s upstate region. By specializing in the collection, hauling, removal and recycling of debris, garbage and waste from construction and demolition sites and, now, through vertical integration, the company is growing, expanding its reach, and adding new services to its portfolio, all at affordable rates.

Comprehensively, National Waste offers trash collection services, roll-off services, a construction and demolition landfill, and a full-service transfer station. For industrial and residential markets, it provides demolition, mulch, gravel and wood grinding services. Lastly, for construction and clean-up projects, it supplies commercial and residential dumpster services and roll-off boxes, as well as construction and demolition landfill services.

National Waste pursues its goal of vertical integration through organic growth initiatives and complementary strategic acquisitions, a strategy that calls for at least one acquisition per quarter so as to diversify the company’s income streams.

National Waste’s acquisition of Northeast Data Destruction and Recycling at the end of 2016 confirmed its management team’s commitment to this assertive business model. It also expanded the company’s business in the upstate New York region of Kingston, where it had already established a presence and was successfully meeting the demand for cardboard recycling and document destruction, hard drive destruction, and other data destruction. With this most recent acquisition, however, the company’s sales team can now also provide roll-off services and additional offerings, and the company is free to pursue plans to set up a physical base in the area – either through a lease or a purchase.

For more information, visit the company’s website at www.nationalwastemgmt.com

Let us hear your thoughts: National Waste Management Holdings, Inc. Message Board

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), on February 1, 2017, named Michael R. Dougherty to its board. A biopharmaceutical company, Marinus is preparing to initiate phase 2 studies of ganaxolone, a drug which treats seizures and anxiety in patients suffering from epilepsy and neuropsychiatric disorders.

Dougherty has more than 30 years of experience in the biopharmaceutical industry. Most recently, he served as executive chairman of Celator Pharmaceuticals, Inc. Earlier, he served as CEO and a board member of Kalidex Pharmaceuticals, Inc. Dougherty also served in various capacities during his 10-year tenure with Adolor Corporation, including as president and CEO, a board member, COO, CFO and senior VP of commercial. Earlier still, he was at Genomics Collaborative, Inc., where he held the positions of president and COO. Dougherty is currently serving on the boards of Trevena, Inc.; Foundation Medicine, Inc.; Aviragen Therapeutics; and Cempra, Inc.

“This is an exciting time to join the Marinus board,” Dougherty stated in a news release. “Marinus is positioned to execute on several clinical studies with near-term milestones. I look forward to working with the Marinus board and management as we advance the development of the ganaxolone franchise.”

Ganaxolone is a drug candidate that acts on a well-characterized target in the brain and is known to have both anti-seizure and anti-anxiety effects. It is currently being evaluated in IV, capsule and liquid forms, and it’s designed for use in both hospital and home settings. Marinus is studying ganaxolone as a treatment option for both adult and pediatric patients.

Marinus is now preparing to begin a phase 2 clinical study of ganaxolone for the treatment of postpartum depression and status epilepticus (SE). A phase 2 clinical study of patients with SE will begin in 2017, the company said. Every dose regimen of ganaxolone IV to-date has been deemed generally safe and well-tolerated, reaching targeted dose levels in a short period of time. Any adverse events reported were mild and resolved without intervention, according to Marinus. Ganaxolone IV has been issued orphan drug designation from the U.S. FDA for the treatment of SE.

For more information, visit www.MarinusPharma.com

Until recently, virtual reality was typically the stuff of science fiction, a concept so innovative and unusual that it seemed highly unlikely to become reality anytime soon. For years, the concept remained almost exclusively tied to the futuristic images depicted by movies such as TRON or The Lawnmower Man. However, with rapid technological advancements in recent years, and due to the efforts of companies such as Facebook (NASDAQ: FB), with its Oculus VR, and Sony Corporation (NYSE: SNE), with its PlayStation VR, virtual reality has now become a part of our day-to-day lives, already having multiple applications in a number of industries, from health care to manufacturing, education, music, athletics and more.

Estimated to reach $126 billion by 2020, this fast developing market presents numerous growth opportunities for developers of VR products, apps and accessories. Simi Valley, CA-based Monster Digital, Inc. (NASDAQ: MSDI), a highly versatile designer and manufacturer of state-of-the-art consumer electronics and related products, has already seized the opportunity with its exclusive line of virtual reality products that includes high definition cameras and headsets, all designed and commercialized under its own brand.

Founded in 2010, Monster Digital is committed to manufacturing and delivering premium products and accessories for consumers and professionals who demand and expect to receive the very best. Its VR Product line includes the recently launched Monster Vision™ 360-degree VR camera, the Monster Vision™ VR camera set, two types of VR headsets (one of which has integrated headphones), and related accessories such as a waterproof VR camera case. The Monster Digital™ VR cameras allow users to record their adventures in a new way and to then share them with their friends and family or experience them from an entirely new perspective due to the 360-degree viewing capabilities.

In addition to VR products, the company also manufactures and commercializes a line of premium action sports cameras such as the high resolution Monster Digital™ Vision Plus 1080p+ camera and the more cost-competitive 720p action sports camera. Most of these models were on display at the Consumer Electronics Show in Las Vegas in early January.

Monster Digital also offers advanced data storage and memory products for use in mobile devices, cameras, tablets and more. The company’s data storage products are built to offer rapid transfer rates and high performance packed in a rugged, sturdy design. Available in multiple capacities, these memory products aim to help users achieve the best performance out of their devices. Additionally, Monster Digital designs the latest technology when it comes to solid state drives (SSD). The company’s SSDs offer peak performance and safe storage and are available both as external drives for desktop and laptop users, as well as internal upgrade kits for Apple (NASDAQ: AAPL) Macbook® and Intel (NASDAQ: INTC) Ultrabook® users.

For more information, visit www.MonsterDigital.com

ChineseInvestors.com, Inc. (OTCQB: CIIX) filed form 10Q with the SEC on January 23, 2017, stating that it had sharply higher revenues in both the quarter and six months ended November 30, 2016, as compared to the same periods of the prior year. In this filing for its second quarter in fiscal year 2017, it also revised its financials for the year ended May 31, 2016, terming that refiling an immaterial correction.

The company reported revenues of $510,944 for the three months ended November 30, 2016. That marked a 133% jump compared to revenues of $219,263 for the same period of the prior year. For the six months ended November 30, 2016, its revenues were $852,268, a 121% increase compared to $385,592 from the same period of the prior year. In the filing, CIIX attributed the gains to more advertising, additional personnel in the U.S. and China, sophisticated new promotions such as multi-media and roadshows, and greater servicing of a larger base of clients.

ChineseInvestors.com, Inc., a financial consulting company, operates a website for Chinese speaking investors located in China and the U.S. It offers consulting, educational products and other services. Its primary revenue streams had been subscriptions and investor relations. It announced plans to open, in January 2017, a retail store in Shanghai and distribute Cannabidiol (CBD) products online on the ChineseCBDoil.com site. The site went live in January 2017, giving CIIX an important marketing opportunity in China and Asia.

Marijuana is not legal in China, but oils that are cannabis-based are. ChineseInvestors.com, Inc., will market health oil products to the Chinese people, it said. The company has attracted significant interest from the financial markets due to these cannabis marketing plans and presented on January 31, 2017, at the NobleCon13 Investor Conference in Florida.

On January 19, 2017, the company filed a Form D Notice to the SEC, disclosing that, through a private placement, it was offering five million shares of its Series C preferred stock at $1 per share. ChineseInvestors.com Inc., said funds raised will be used for operating activities and to retire a $660,000 loan, which has a maturity due date of February 28, 2017. As of January 23, 2017, the company said it had raised $4.7 million in cash from various individuals.

In the 10Q, it said it under reported its revenue by $42,500 for the year ended May 31, 2016. On its balance sheet, as of May 31, 2016, total assets were under reported by $171,600, total liabilities were understated by $2,575, and total shareholders’ equity was understated by $169,025. It said it plans to revise its financial statements for some quarterly periods through subsequent filings.

For more information, visit the company’s website at www.ChineseInvestors.com

Zogenix, Inc. (NASDAQ: ZGNX) has been issued a patent by the U.S. Patent Office for its drug candidate ZX008. The award of this patent, according to the company, marks the first time a patent has been issued covering a fenfluramine treatment of Dravet Syndrome and the seizures associated with it (http://dtn.fm/v69uD). The patent is seen by the company as offering protection of associated claims through 2033.

“This represents the first issued patent covering the treatment of seizures associated with Dravet Syndrome using fenfluramine as an adjunctive therapy, and it is an important milestone for our ZX008 development program,” Stephen J. Farr, Ph.D., president and CEO of Zogenix, added in a news release.

The patent, titled ‘Method for the Treatment of Dravet Syndrome’, was announced by the company on January 30, 2017. Zogenix is currently in a phase 3 program with ZX008 and continues to enroll patients in the U.S. and globally. It has received fast track designation domestically for the treatment of Dravet syndrome, and ZX008 has been defined as an orphan drug in this indication in both the U.S. and Europe.

Zogenix, Inc., is a pharmaceutical company committed to producing commercially-viable central nervous system (CNS) therapies. The company is developing these products for individuals who require innovative treatments to help them with daily functioning.

Farr added that Zogenix is continuing to pursue additional patents related to ZX008 in order to provide additional protection for its lead candidate. The company is also performing more clinical and preclinical work as it seeks to target more intellectual property opportunities, he said.

Zogenix won worldwide patent rights and other intellectual property via its 2014 acquisition of Brabant Pharma Limited, pursuant to a purchase and sales agreement executed with Brabant, the company said.

In its SEC filing of November 8, 2016, Zogenix reported that, in October 2016, it extended through April 2017 its manufacturing services agreement with Pantheon UK Limited. It can be extended again, the company reported. Future purchase minimum obligations totaled $4.6 million at September 30, 2016, through the extension date.

Also on October 2016, Zogenix entered into an asset purchase agreement for $1.5 million to buy the global rights to a preclinical development program for orphan CNS disorders. The company is bound to make future milestone payments over several years, but in the SEC filing Zogenix termed those payments ‘inherently uncertain’ due to the preclinical stage of development.

For more information, visit www.Zogenix.com

Travel to far and remote destinations is easier than it has ever been. Travel companies have not only made traveling accessible, but also more economical. People are now able to explore some of the remarkable destinations our world holds, including natural wonders and historical sites. However, some of these places are in danger of disappearing.

Climate change, over farming, natural erosion, pollution, urbanization and general exploitation, are just some of the causes for the potential loss of these places. Although environmental organizations recognize the threat and are putting in place procedures to maintain these destinations for as long as possible, they remain at risk. According to Business Insider (http://dtn.fm/ctV1K), some of these endangered destinations include the Great Wall of China, the Taj Mahal, Australia’s Great Barrier Reef, the Florida Everglades, and many other famous destinations.

Monaker Group, Inc. (OTCQB: MKGI), a technology driven travel company, is making these destinations accessible through its subsidiary, Maupintour. Founded by Tom Maupin in the 50’s, Maupintour gives solo travelers and groups the chance to organize highly customizable private tours across the globe, including to threatened destinations.

Tours organized through Maupintour cover many extra features that, if organized separately, would cost much more, such as local guides, great accommodations, comprehensive tours, special events, entertainment, entrance fees, airport transfers, and hotel transfers.

The company organizes tours to Europe, Africa, Central and South America, Asia and India, Australia and New Zealand, as well as throughout the United States. Maupintour has the highest repeat rate in the industry, with some travelers taking up to 60 vacation tour packages with the company. Maupintour tours make natural and man-made wonders of the world accessible to travelers at an affordable price, while they are still there to see.

For more information, visit www.MonakerGroup.com

CytoDyn Inc. (OTCQB: CYDY) is set to profit from helping the HIV positive with its lead product candidate, PRO 140. The company is close to submitting a rolling Biologics License Application (BLA) for PRO 140 as a combination therapy with highly active antiretroviral therapy (HAART).

The biologic has already been designated a “fast track” product candidate by the FDA, and, earlier this month, the company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a treatment for HIV-1 infection in treatment-experienced patients with virologic failure. Getting PRO 140 to market means CytoDyn Inc. will be entering the $15 billion industry for HIV therapies in the U.S.

Data released by the National HIV Surveillance System and Medical Monitoring Project reveals the market opportunities. There are an estimated 1.2 million people in the U.S. living with HIV. However, about 168,000 of those, some 14 percent of those infected, are unaware that they are HIV positive. The remaining 1,032,000 know they have the virus, yet just 40 percent (480,000) are under care.

Why this is so has prompted a number of studies. Researchers in the European Union and Australia conducted a number of surveys of the HIV positive and the doctors who treat them. They found that the major reason why those carrying HIV eschew treatment is that they do not feel sufficiently unwell or have symptoms serious enough to hasten entry to treatment. The studies also revealed ‘that 47% of respondents did not wish to start therapy because they did not want to be reminded about their HIV status’.

Of the 480,000 HIV positive patients who are being treated, about 92.5 percent, or 444,000, have been prescribed antiretroviral therapies. Meanwhile, just 360,000, or 75 percent of the HIV positive population under care, have been able to achieve viral suppression.

PRO 140 has the greatest potential as a mono-therapy, if replacing HAART as a first-line or higher therapy. This is a market of 460,000 people estimated at $11 billion. As a combination therapy replacing second line therapy and higher, the prospect is also attractive. With 207,000 patients falling into this segment, this is a market that could yield over $5 billion. In addition, as the stigma of HIV/AIDS lessens, it is likely that more of the HIV positive will be encouraged to start treatment, bringing over half-a-million into the fold.

PRO 140 is a viral-entry inhibitor, a new class of HIV/AIDS therapies that work by blocking the entry of the human immunodeficiency virus (HIV) to healthy cells. It is currently being evaluated in two Phase III trials and, in one of those, a pivotal Phase III trial testing PRO 140 as a combination therapy, primary endpoint results are expected during the first half of this year.

The second Phase III trial, testing PRO 140 as a mono-therapy, is also going well. The company announced in December 2016 that the first patients had been treated in a multi-center, open-label trial. For the HIV positive, this is positive news from CytoDyn Inc.

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. In trials, its lead product candidate, PRO 140, has shown it can significantly reduce viral burden in those infected with HIV. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non-HIV indications where similar autoimmune responses are involved.

For more information, visit www.CytoDyn.com

GreeneStone Healthcare Corp. (OTCQB: GRST), through its subsidiaries, provides medical services in the city of Toronto and the regional municipality of Muskoka, Ontario, Canada.

Located 90 minutes north of Toronto in Muskoka, GreeneStone Healthcare’s Addiction and Rehabilitation Treatments segment offers out-patient counseling, coaching, intervention, psychological assessment, and other related services.

GreeneStone Muskoka employs the best principles and practices currently available in the treatment of individuals with addiction. To ensure the most comprehensive and effective treatment for its clients, GreeneStone Muskoka treats underlying or co-occurring disorders in tandem with the treatment of addiction.

The 36-bed addiction treatment center offers a holistic, individualized treatment approach to recovery. These private, paid programs vary in length from 45-90 days, depending on the unique needs of each resident and their response to the treatment.

GreeneStone Muskoka also provides education and counseling sessions to educate the family members of its residents with the objective of helping them better understand the disease of addiction and how they should support their loved ones throughout and after their recovery efforts.

GreeneStone Healthcare President Shawn Leon has more than 25 years of experience managing public and private development-stage companies for various industries, including industrial minerals, aggregates, oil and gas, mining, finance, technology, hospitality and medical. He has provided financing and capital markets oversight for a number of these ventures, many of which have involved negotiations for mergers and acquisitions. He is joined by Vice President Dr. Anita Teslak, whose 25 years of combined experience as a CEO, psychologist and executive provides valuable insight into a successful business model.

For more information, visit the company’s website at www.GreeneStone.net